Today marks an important milestone for Kraig Labs and, with it, the opportunity to share an update across all aspects of our operations. This letter format allows us to share a more broad-reaching update on multiple aspects of our operations, ranging from finance and next-generation technologies to commercialization.

On November 21^st, we announced that we had eliminated all convertible debt to our financing partner. I am happy to announce that as of December 9^th, 2022, they no longer hold any shares or selling interest in the Company’s stock, which eliminates selling pressure from that source. Just over two years ago, we began the journey to strengthen the Company’s balance sheet with the injection of $8 million in growth capital. This capital has played a critical role in the growth of our production operations and the evolution from technology creation to product development.

Over the last 24 months, Kraig Labs deployed just under half of this capital to build out the commercial-scale production operations needed to transition our spider silk technology from pilot operations to our current multipronged production system with the capacity for metric tons of silk production. We made critical investments in infrastructure, personnel, equipment, and training to build, what we believe, is the most advanced silkworm-rearing facility in Vietnam. Over the summer, we shared a two-part video series bringing viewers inside this facility.

We leveraged a portion of this growth capital to invest in a partnership with a third-party contract manufacturer. This funding has also allowed us to sign a long-term, multi-ton contract manufacturing agreement with this third-party producer. We first announced this partnership in July 2022 and shared with you that they required 90 days to ramp up before they could start delivering silk. We received the first batch of silk from this supplier right on schedule. While it was our largest single-month production batch to date, it did not meet the target we had for their first production batch. The shortage in production output for the first shipment is tied to the acclimation and conditioning of our silkworm line to the local production environment. 

Kraig’s US and Vietnam teams are working closely together with the third-party producer to address the hurdles they are facing in an effort to rapidly grow production capacity. In addition to the ongoing efforts to boost production through the acclimation of our silkworm lines to the local climate, we are also accelerating the introduction of a multiple-strain hybrid silkworm model used in conventional silk production to increase robustness. We remain confident that implementing these processes and technologies is the best path to successfully grow our production output to match the targeted metric ton per month levels we have contracted with them to produce by late 2023.

While the current focus remains on the rapid commercialization of existing spider silk technologies, the Company’s R&D efforts remain focused on extensive opportunities for our spider silk technologies, fibers, and proteins. Work with our third-party contract manufacturer has identified opportunities and incentives to accelerate our multi-line hybrid production models. Ramp-up of this work is already underway in the Company’s US facilities, and we expect this will be ready for the transition to production in Q1 2023.

The first phase of this program will be the transition to single-line cross-hybrids, which we developed in our labs over the last six months to boost resilience and environmental tolerance. Upon successful deployment, we will transition into the second phase of this program with the introduction of a multi-strain cross-mating program for all production operations. Our target is single strain hybrid rollout in Q1 and dual strains for the utilization of first-generation hybrids as early as Q2. This system will closely mirror the processes used for mundane silk egg production and should result in both larger cocoons and more resilient silkworms. This technology has been validated in our R&D labs and is now being scaled up for the transition to large-volume operations with our third-party production partner.

Market demand for our silks still outpaces our in-house production capacity. The spider silk we have in inventory is dedicated to the first apparel launch from SpydaSilk, our joint venture brand with Kings Group in Singapore. The Kraig and Kings Group teams are working together closely to create SpydaSilk and our collective vision for the brand. Starting from this conceptual brand identity and ethos, we have created product concepts that we are now working to bring to life.

This summer, we announced hiring a leading textile expert to help us develop custom yarns and fabrics based on our unique spider silk materials. Over the last few months, this work has sent us on a global search for the best yarn spinners and mills. Our team has reached out to well over 100 of the top spinners of high-end yarns as part of our search to identify the best long-term partner. Guided by the counsel of our textile consultant, we developed what we believe to be the first of many new concept yarns and we are now in the process of having these vendors complete sample trials.

 Outside of SpydaSilk, the Company continues to develop additional markets and opportunities for our materials. Opportunities in the protective and defensive textiles markets are at the top of the Company’s list for collaborative developments.

The opportunities and investments made possible over the last 24 months due to the $8 million in growth capital cannot be understated. With the careful deployment of a portion of this funding, we have built out a state-of-the-art breeding facility in Vietnam, advanced the state of our transgenic spider silk technologies in the labs, invested in the creation of the SpydaSilk apparel brand, worked to develop the first custom yarns and fabrics, and most critically invested into commercial scale spider silk production in partnership with our third-party contract manufacturer.

Over the last two-plus years, our world and our Company have faced unprecedented challenges. While times have been tough for many of us, Kraig had the good fortune and forethought to access capital ahead of many of these challenges. We have now paid off the cost of that capital both in terms of the elimination of conversable debt and the liquidation of the financer’s equity position.

As we turn our eyes toward 2023, we will enter the new year with a strengthened balance sheet, capital reserves, a strengthened R&D program, and significant production infrastructure. The biggest immediate hurdle to large-scale production is the robustness of our silkworms within the large-scale production environment. Our hybridization program, which is explicitly designed to increase robustness and cocoon size, is in an advanced state and will be rolled out in stages in early and mid-2023.

At Kraig, our plan is to make 2023 the year when spider silk production hits truly commercial scale, with robust hybrids and spider silk-based products beginning to make inroads into end product markets. 

Season’s Greetings, Happy New year, and Merry Christmas to all of our shareholders and to the world.

Kim Thompson, CEO

Kraig Biocraft Laboratories, Inc.

Ann Arbor, MI., November 21, 2022 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that it has completed the debt-to-equity conversion on $8 million of convertible debentures with Yorkville Advisors. This closeout comes several months ahead of schedule and positions the Company to enter 2023 without any convertible debt obligations to Yorkville Advisors.

The Company would like to thank Yorkville Advisors and Maxim Group for supporting its vision to transform the textile markets with large-scale production of cost-effective and eco-responsible spider silk. 

Kraig Labs currently has more than $4.5 million of deployable liquid assets and will continue to use this capital to develop end-market products and strengthen the supply chain creating its revolutionary spider silk technologies. 

“While this financing has been a critical element of our transition to commercialization, we are pleased to report that we have eliminated the burden of this debt and enter the holiday season in a solid financial position. We continue to judiciously deploy this capital to build out our spider silk production capacity. Our focus now is on increasing that production, including further strengthening our production infrastructure. An important part of that program is the planned rollout of new hybrids. Our target remains metric ton production,” said CEO Kim Thompson.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Ann Arbor, MI., – September 12, 2022 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that it has contracted Jeff Dorton, a top textile expert to assist the Company in developing new and innovative yarns and fabrics utilizing Dragon Silk™.

Kraig Labs is leveraging Mr. Dorton’s expertise and proven record of innovation in textiles to create new and exciting composite yarns and fabrics utilizing spider silk. The initial customer for these yarns and fabrics will be Spydasilk Enterprises, the Company’s joint venture apparel brand, headquartered in Singapore. Following the launch of Spydasilk apparel, the Company plans to expand collaboration with Mr. Dorton to create several additional yarns and textiles, for applications spanning the performance and luxury textiles market and beyond.

Mr. Dorton brings a passion for material development, a proven track record of innovation, and a wealth of experience working with some of the best textile mills worldwide. He has led some of those most disruptive innovations in next-generation textiles that permeate the performance wear segment.

Utilizing his extensive network of mills and spinners around the globe, Mr. Dorton is currently working to drive the manufacture of the first spider silk fabrics.

“I have known Jeff since his time with The North Face, and I am thrilled to partner with him to create Kraig Labs’ first custom yarns and fabrics. Jeff is a highly regarded textile expert with a storied history of developing new textile technologies. He has directed key initiatives for some of the planet’s biggest brands, and we can’t wait to see what we can do together. While his ability to develop high-performance yarns and fabrics may be unmatched, we share Jeff’s passion for sustainability and textiles that are functional and desirable,” stated Company COO Jon Rice.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Jeff Dorton

Dorton is Vice President of Product Development and Material Innovation at LifeLabs Design. Previously he directed material innovation efforts for The North Face and Under Armour.

Dorton’s career highlights include developing Intellectual Property in fabric and insulation commercialized by leading performance wear brands around the globe. He has balanced this work in innovation with a solid commitment to environmental responsibility and drive to sustainability. Dorton led initial efforts to develop Nano spun membrane called FutureLight, the most advanced fabric and largest commercial launch in The North Face’s (TNF) history. Dorton expanded the franchise offering of “Thermoball” insulation through construction and material innovation for TNF. He coordinated with the sustainability team at VF Corporation to create the Responsible Down Standard that was later gifted to Textile Exchange to ensure ethical and sustainable sourcing for natural insulations. Dorton assisted in moving the entire supply chain at TNF to a more eco-friendly C0 DWR finish and shifted over 80% of fabrics into recycled content.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Ann Arbor, Michigan., – August 17, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that the Company has now been granted a business license to begin operations in Lam Dong Province. 

The newly established business license and facility in Lam Dong Province are part of the Company’s expansion into the Vietnamese highlands, the center of silk production in Vietnam. The highlands of Lam Dong Province offer temperate climates ideal for silkworm rearing and ready access to the cocoon and silk spinning facilities currently producing several hundred metric tons of mundane silk per year. 

In June, management from Kraig Labs traveled to Lam Dong for meetings with officials from the Lam Dong Agro-Forestry Research Experiment Center (LAREC) to assess the opportunities to expand silk production into the province and to tour the regional support infrastructure.   The LAREC operates as the authority in Vietnamese sericulture, maintaining 47 unique species of Vietnamese silkworms. The LAREC has developed multiple varieties of mulberry, including S7-CB, which has doubled production yields, from about 25-30 metric tons of foliage per hectare, for standard mulberry, to 50-60 tons of foliage per hectare, for the S7-CB mulberry strains. Kraig Labs planted with S7-CB mulberry at its facilities in Quang Nam, which has resulted in similar improvements.

The Company’s Vietnamese headquarters will remain in Quang Nam at its breeding and production center. This facility was recently featured as part of the Company’s behind-the-scenes video series, www.kraiglabs.com/videos. The Quang Nam facility is designed to produce and supply all of the Company’s proprietary silkworm eggs for in-house and 3^rd party contract manufacturing.

“Lam Dong is the center of silk production in Vietnam. We are pleased to report that, with the granting of this business license, Kraig Labs and our specialized spider silk silkworm technologies are now being woven into the proud history and bright future of Vietnamese sericulture,” said Company COO Jon Rice.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk-based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could,” “will” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Ann Arbor, Michigan., – August 4, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces the release of the second behind the scenes look into its recombinant spider silk production operations. This video brings the viewer inside the laboratories at its R&D facility in the U.S. and its quality control lab at its production facility in Vietnam. 

This video tour edition highlights the laboratory facilities and the team of dedicated researchers and scientists creating and commercializing the world’s first cost-effective and eco-responsible spider silk.

“Our research and quality assurance teams are leading the way, creating and commercializing some of the most amazing materials on earth,” said Company COO Jon Rice.

Interested viewers can find the video at www.kraiglabs.com/videos or through the Company’s YouTube Channel https://youtu.be/xX6z_e7gyvA, where they can subscribe to be notified of future video releases in this series.

In upcoming video releases, the Company expects to bring viewers along for tours inside the rearing and breeding operations and the opportunity to meet some of the team creating tomorrow’s super fibers.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk-based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could,” “will” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Ann Arbor, Michigan., – August 1, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that representatives of its apparel brand SpydaSilk^TM attended Vietnam’s premiere textile and garment industry exhibition, SaigonTex.

Since 1990, SaigonTex has brought together the largest collection of producers, suppliers, and buyers from Europe and Asia in the textile, fabric, and garment industry. Last week’s exhibition marked the event’s first return since 2019 after two years of COVID-19-related cancellations.   

The SpydaSilk team attended the Expo as part of its efforts to grow its network of suppliers. The team is working quickly to identify and partner with industry leaders capable of creating one-of-a-kind customer yarns and fabrics built upon Kraig Labs’ recombinant spider silk technologies. These new exclusive yarns and fabrics will be the foundation of SpydaSilk’s brand identity.    

“We are happy to see the return of SaigonTex, Vietnam’s premiere textile exhibition. The re-opening of this major international exhibition is evidence that the textile industry is roaring back. This event was a great opportunity for members of our SpydaSilk team to network with many new potential production partners as we work towards the first apparel launch,” said Company COO Jon Rice.

The Company expects to release the second video in its behind-the-scenes series taking viewers inside its spider silk production facilities next week. This episode will bring you inside the R&D labs at Kraig and Prodigy as the team works to create tomorrow’s super materials and monitors the performance and quality of current Dragon Silk^TM production.

For those who missed the first episode in this video series, it can be found at www.kraiglabs.com/videos or through the Company’s YouTube Channel https://youtu.be/qeM2hzXbtRM, where viewers can subscribe to be notified of future video releases in this series.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk-based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “will”, “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Ann Arbor, Michigan., – July 20, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces the release of a behind the scenes look into its silkworm breeding facility in Vietnam. This video is the first in a series designed to bring the viewer inside the Company’s recombinant spider silk production operations. 

This video tour edition highlights the breeding and egg production center that the Company established in Vietnam, to support in-house and third-party contract manufacturing of its eco-responsible and cost-effective spider silk.

Operated by its wholly owned Vietnamese subsidiary, the Company believes that this facility is now equipped to meet the production demand for its proprietary specialized spider silk silkworm eggs through 2025 and has the capacity to expand far beyond that.

“Our team has built out what we believe to be one of the most advanced silkworm breeding facilities in the world. We are excited to share these first behind-the-scenes looks into our operations and to bring the viewers along on this incredible journey bringing our eco-responsible cost-effective spider silk to the global consumer markets,” said Company COO Jon Rice.

Interested viewers can find the video at www.kraiglabs.com/videos or through the Company’s YouTube Channel https://youtu.be/qeM2hzXbtRM, where they can subscribe to be notified of future video releases in this series.

In upcoming video releases, the Company expects to bring viewers along for tours inside the R&D and quality control labs as well as the feeding, rearing, and breeding operations.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk-based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com